Are durva/cis/gem or pembro/cis/gem less efficacious in cholangiocarcinomas with FGFR2 fusions?

I have not been able to find an answer to this question. The NCCN and French National Clinical Practice Guidelines both continue to recommend first line treatment with Gemcitabine/Cisplatin and Durvalumab. Exceptions include NTRK gene fusions and MSI-H/dMMR where NTRK inhibitors (e.g. entrectinib, l...